<u>CURRICULUM VITAE</u> JOSEPH TAUBER, M.D.

Tauber Eye Center 4400 Broadway, Suite 202 Kansas City, MO 64111 (816) 531-9100 (816) 531-9105 FAX jt@taubereye.com

T 1 40	
Education	n
Luucauv	

1978 Bachelor of Sciences in Biology and Chemistry

Union College Schenectady, N.Y.

1982 Doctor of Medicine

Harvard Medical School Boston, MA

Postdoctoral Training

7/82-6/83 Internship in Internal Medicine

Northwestern Medical Center Chicago, IL

7/83-6/84 Residency in Internal Medicine

Beth Israel Hospital Boston, MA

7/84-6/87 Residency in Ophthalmology

Tufts-New England Medical Center Boston, MA

7/87-6/88 Fellowship in Ocular Immunology

Massachusetts Eye & Ear Infirmary Boston, MA

7/88-6/89 Fellowship in Corneal and External Diseases

Massachusetts Eye & Ear Infirmary Boston, MA

Licensure and Certification

1983 Diplomate National Board of Medical Examiners

1984 Massachusetts State Licensure1989 Missouri State Licensure

1989 Diplomate of the American Board of Ophthalmology

1997 Kansas State Licensure

Academic Appointments

1999-2011 Clinical Professor of Ophthalmology

Kansas University School of Medicine

1999-Present Medical Director

Saving Sight Eye Bank

1998-1999 <u>Clinical Professor of Ophthalmology</u>

University of Missouri-Kansas City School of Medicine

1994-1997 Clinical Associate Professor of Ophthalmology

University of Missouri-Kansas City School of Medicine

1989-1993 Clinical Assistant Professor of Ophthalmology

University of Missouri-Kansas City School of Medicine

1991-1999 Director of Clinical Research

University of Missouri-Kansas City School of Medicine

Hospital Staff Appointments

1989-Present St. Lukes Hospital of Kansas City-Kansas City, MO

Honors, Awards and Distinctions

Union College Valedictorian, Summa Cum Laude

William E. Lasnik Prize

Harvard

Medical School Founding Member Cabot Medical Society

Northwestern Co-chairman House Staff Committee **Medical Center** Northwestern Memorial Hospital

Tufts-New England

Medical Center Charles J. Preefer Resident Research Award

Massachusetts National Eye Institute Individual NRSA Award Eye & Ear (EY06052) 1987-1989

Infirmary

Heed Ophthalmic Foundation Fellowship 1987-88 Heed Foundation/Knapp Fellowship 1988-89

Post - Training American Academy of Ophthalmology Achievement Award, 2005

American Academy of Ophthalmology Program Committee

Member, Cornea Subcommittee 2002 - 2006

Professional Affiliations

American Academy of Ophthalmology

Association for Research in Vision and Ophthalmology

Cornea Society

Metropolitan Medical Society of Greater Kansas City Kansas City Society of Ophthalmology & Otolaryngology

Midwest Corneal Society

Versatile Method for Evaluating a Cell Culture by Various Morphological Techniques.

Lahav M, Ishii Y, Craft J, Tauber J.

Stain Technology 57: 331-347, 1982

Cryotherapy for Iris Neovascularization and Neovascular glaucoma.

Lahav M, Tauber J, Haug S.

Ocular Circulation and Neovascularization ed. By D BenEzra, SJ Ryan, BM Glaser And RP Murphy,

Documenta Ophthalmologica Proceedings, Series 50, pp. 383-386,

Martinus Nijhoff/DR W Junk Publishers, 1987

New Clinical Classification for Iris Neovascularization.

Tauber J, Lahav M, Erzurum SA.

Ophthalmology 94 (5): 542-544, 1987

Simplified Diagnostic Coding Sheet for Computerized Data Storage and Analysis in Ophthalmology

Tauber J, Lahav M.

Ophthalmic Surgery 18 (11): 846-849, 1987.

Dramatic Improvement Following Plasmapheresis in the Atopic Keratoconjunctivitis Associated with Hyper IgE Syndrome.

Aswad M, Tauber J, Baum J.

Ophthalmology 95 (4): 444-447, 1988.

Cataract Surgery in Ocular Cicatricial Pemphigoid.

Sainz de la Maza M, Tauber J, Foster CS.

Ophthalmology 95 (4): 481-486, 1988.

Lymphocyte Proliferation After HSV-1 Infection in Igh-1 Disparate Congenic Murine Strains.

Tauber J, Wells PA, Foster CS.

Investigative Ophthalmology Visual Science 29 (Suppl): 152, 1988.

Scleral Grafting in Necrotizing Scleritis.

Sainz de la Maza M, Tauber J, Foster CS.

Ophthalmology 95 (9) Suppl: 161, 1988.

Glaucoma in Patients with Ocular Cicatricial Pemphigoid.

Tauber J, Melamed S, Foster CS.

Ophthalmology 96 (1): 33-37, 1989

Systemic Immunologic Responses Following Intracameral Inoculation of HSV-1 in

Susceptible and Resistant Igh-1 Disparate Congenic Murine Strains.

Tauber J, Hemady R, Ihley T, Opremcak EM, Foster CS.

Investigative Ophthalmology Visual Science 30 (Suppl): 359, 1989.

Value of Conjunctival Biopsy in Peripheral Ulcerative Keratitis.

Sainz de la Maza M, Foster CS, Tauber J, Hoang-Xuan T.

Ophthalmology 96 (9) Suppl: 121, 1989.

An Analysis of Therapeutic Decision Making in Peripheral Ulcerative Keratitis.

Tauber J, Hoang-Xuan T, Sainz de la Maza M, Foster CS.

Cornea 9 (1): 66-73, 1990.

Viral Isolation and Systemic Immune Responses After Intracameral Inoculation of Herpes

Simplex Virus type 1 in Igh-1 Disparate Congenic Murine Strains.

Hemady R, Tauber J, Ihley TM, Opremcak EM, Foster CS.

Investigative Ophthalmology Visual Science 31 (11): 2335-2341, 1990.

Ocular Cicatricial Pemphigoid (OCP) – The Potential for Cure.

Neumann R, Tauber J, Foster CS.

Ophthalmology 97 (9) Suppl: 132, 1990.

Systemic Chemotherapy for Ocular Cicatricial Pemphigoid.

Tauber J, Sainz de la Maza M, Foster CS.

Cornea 10 (3): 185-195, 1991.

Romberg's Progressive Hemifacial Atrophy: An Association with Spontaneous Scleral Melting.

Hoang-Xuan T, Foster CS, Jakobiec FA, Tauber J, Sainz de la Maza M, Krebs W.

Cornea 10 (4): 361-366, 1991.

Immunomodulators in Immune and Inflammatory Diseases of the Eye.

Hemady R, Tauber J, Foster CS.

Survey of Ophthalmology 35 (5): 369-385, 1991.

Investigation and Treatment of Peripheral Corneal Ulcers.

Foster CS, Tauber J, Sainz de la Maza M, Hoang-Xuan T.

In 4th Worksop on External Eye Disease & Inflammation, Medical Communications Services Limited, Oxted, Surrey. pp. 13-21, 1990.

Remission and Recurrence after Withdrawal of Therapy for Ocular Cicatricial Pemphigoid.

Neumann R, Tauber J, Foster CS.

Ophthalmology 98: 858-862, 1991.

Lipemia Retinalis

Martinez KR, Cibis GW, Tauber J.

Archives of Ophthalmology 110: 1171, 1992.

Improved Detection of Disease Progression in Ocular Cicatricial Pemphigoid.

Tauber J, Jabbur N, Foster CS.

Cornea 11 (5): 446-451, 1992.

The Effectiveness of Excimer Photorefractive Keratectomy for Myopia.

Piebenga LW, Deitz MR, Irvine JW, Matta CS, Tauber J, Sabates FN.

Ophthalmology 99 (9A): 106, 1992.

Long Term Results of Systemic Chemotherapy for Ocular Cicatricial Pemphigoid.

Foster CS, Neumann R, Tauber J.

Doc Ophthalmology 82 (3): 223-229, 1992.

Kayser-Fleisher Ring of the Cornea Associated with Non-Wilsonian Liver Disease.

Tauber J, Steinert RF.

Cornea 12 (1): 74-77, 1993.

Improvement in Squamous Metaplasia Following AquasiteTM Treatment in Patients with

Dry Eye Syndrome and in Normal Volunteers.

Tauber J, Crosser VA, Mardelli PM.

Investigative Ophthalmology Visual Science 34 (4): 2693, 1993.

Regional Impression Cytology Abnormalities in Normal Volunteers.

Rupani M, Crosser VA, Tauber J, Mardelli PM.

Investigative Ophthalmology Visual Science 34 (4): 2693, 1993.

Corneal Topographic Abnormalities Following the Use of Artificial Lubricants.

Mardelli PM, Tauber J, Piebenga LW.

Investigative Ophthalmology Visual Science 34 (4): 3809, 1993.

Comparison of Expanding versus Contracting Diaphragm Movement in Excimer Laser

Photoablation Without Nitrogen Gas Flow.

Drew S, Walline TA, Tauber J, Cobb CJ, Gardner L.

Investigative Ophthalmology Visual Science 34 (4): 490, 1993.

Improvement in Squamous Metaplasia and Tear Osmolarity Following AquasiteTM Treatment.

Mardelli PM, Teague BJ, Tauber J.

Ophthalmology 100 (9A): 108, 1993.

Retreatment of PRK Refractive Failures

Matta CS, Piebenga LW, Deitz MR, Tauber J.

Ophthalmology 100 (9A): 108, 1993.

A Retrospective Review Comparing Iris-Fixated Vs. Open Loop ACIOLs with Penetrating Keratoplasty.

Tauber J, Bealer L, Cavanaugh T, Durrie D.

Journal Of Cataract And Refractive Surgery (Suppl): 71, 1993.

Excimer Photorefractive Keratectomy for Myopia.

Piebenga LW, Deitz MR, Matta CS, Tauber J, Irvine JW, Sabates FN.

Ophthalmology 100 (9): 1335-1345, 1993.

Two Zone PRK for Moderate Myopia.

Piebenga LW, Matta CS, Deitz MR, Tauber J.

Ophthalmology 100 (9A): 108, 1993.

A Multicenter Comparison of Diclofenac Sodium 0.1% (DS) to Ketorolac Tromethamine 0.5% (KT)

in Patients with Acute Seasonal Allergic Conjunctivitis (SAC).

Tauber J, et. al.

Investigative Ophthalmology Visual Science 35 (4): 1291, 1994.

Changes in Corneal Topography After Instillation of Artificial Lubricants.

Yu JS, Wu M, Crosser V, Tauber J.

Investigative Ophthalmology Visual Science 35 (4): 1291, 1994.

Contact Lens and Spectacle Use Before and After PRK.

Jaffe MR, Ranjan MR, Tauber J.

CLAO 20 (Suppl): 48, 1994.

Cicatricial Pemphigoid.

Tauber J, Foster CS.

In: Mannis MJ, Macsai MS, Huntley AC, Eds. *Diseases of the Eye and Skin*, New York, Raven Press, 1995.

Wegener's Granulomatosis.

Tauber J, Hall JC.

In: Mannis MJ, Macsai MS, Huntley AC, eds. *Diseases of the Eye and Skin*, New York, Raven Press, 1995.

Juvenile Rheumatoid Arthritis.

Tauber J.

In: Krachmer JH, Mannis MJ, Holland EJ, Eds. Cornea, St. Louis, CV Mosby, 1996.

Two Zone Excimer Photorefractive Keratectomy for Moderate Myopia. 6 to 18 Month Followup.

Piebenga LW, Matta CS, Deitz MR, Tauber J.

Ophthalmology 102: 1054-1059, 1995.

Duration of Tear Osmolarity Changes Following Instillation of Artificial Lubricants In Patients

With Keratoconjunctivitis Sicca.

Crosser V, Mardelli P, Wu A, Tauber J.

Investigative Ophthalmology and Visual Science 36: S998, 1995.

The Effects of Instillation of Topical NSAIDs on Corneal Sensation.

Tauber J, Garner L, Niknia H, Crosser V.

Investigative Ophthalmology and Visual Science 36: S576, 1995.

Temporary Intracanalicular Collagen Implants In Normal Volunteers.

Tauber J, Garner L, Rioux N.

Investigative Ophthalmology and Visual Science 37: S853, 1996.

Epidemiological Study of Punctal Size in Normal Volunteers.

Rioux N, Garner L, Tauber J.

Investigative Ophthalmology and Visual Science 37: S566, 1996.

Photorefractive Keratectomy Results as a function of Preoperative Astigmatism.

Garner L, Crosser V, Tauber J.

Investigative Ophthalmology and Visual Science 37: S566, 1996.

Five and Three Year Follow-up of Photorefractive Keratectomy for Myopia of -1 to -6 Diopters.

Matta CS, Piebenga LW, Deitz MR, Tauber J, Garner L.

Journal of Refractive Surgery 14:318-324, 1998

Excimer Retreatment for Myopic Photorefractive Keratectomy Failures. Six to 18 Month Follow-up.

Matta CS, Piebenga LW, Deitz MR, Tauber J.

Ophthalmology 103: 444-451, 1996

Ablation Zone Centration after Photorefractiuve Keratectomy and Its Effect on Visual Outcome.

Deitz MR, Piebenga LW, Matta CS, Tauber J, Anello RD, DeLuca M

Journal of Cataract and Refractive Surgery 22(6): 696-701, 1996

The Effects of Instillation of Diclofenac sodium 0.1% on Photophobia following Pupillary Dilation.

A Pilot Study in Normal Volunteers.

Tauber J, Raphtis C.

Investigative Ophthalmology Visual Science 38 (4): S142, 1997

A Multicenter Comparison of the Ocular Efficacy and Safety of Diclofenac 0.1% Solution with that

Of Ketoralac Tromethamine 0.5% Solution in Patients with Acute Seasonal Allergic Conjunctivitis.

Tauber J, Raizman MB, Ostrov CS, Laibovitz RA, Abelson MB, Betts JG, Koester JM,

Gill, D, Schaich L.

Journal of Ocular Pharmacology and Therapeutics 14 (2): 137-146, 1998

Evaluation of Two Different Methods of Epithelial Removal Prior to Excimer Laser

Photorefractive Keratectomy for Myopia.

Tauber J, Cable M, Chavala S, Polepalle S.

Investigative Ophthalmology Visual Science 40 (4): S107, 1999

Refractive Outcomes Following Excimer Laser Photorefractive Keratectomy for Myopia Using

Two Different VISX Excimer Lasers.

Cable M, Matta C, Piebenga L, Polepalle S, Steward C, Tauber J.

Investigative Ophthalmology Visual Science 40 (4): S106, 1999

Safety and Efficacy of Nedocromil Sodium Ophthalmic Solution 25 BID in Patients with Ocular Itch Associated With Allergic Conjunctivitis.

Tauber J, Alocril® Community Ocular Allergy Trial Study Group

Investigative Ophthalmology Visual Science 42(4) S910, March 2001

Efficacy and Safety of Combination Therapy with Brimonidine 0.2% and Latanoprost 0.005% Versus Fixed Combination Timolol 0.5%/Dorzolamide 2%

Zabriskie N A, Ahmed I K, Cantor L B, Kent A B, Mundorf T, Tauber J, Rubin J M, Hoop J

Investigative Ophthalmology Visual Science 42 (4) S833, March 2001

Phase 2 Dose Ranging Efficacy Trial of INS365 Ophthalmic Solution, A P2Y2 Agonist, in Patients with Dry Eye. Foulks G, Sall K, Greenberg M, Tauber J, Donshik P, Berdy G, Sylvester R, Yerxa B, Crockett S,

Kellerman D

Investigative Ophthalmology Visual Science 42 (4) S713, March 2001

Nedocromil Sodium Ophthalmic Solution 2% Twice Daily in Patients with Allergic Conjunctivitis.

Tauber J, and the Alocril Community Allergy Trial Study Group

Advances in Therapy 19 (2) 73-84, March / April 2002

Double-Masked, Placebo-Controlled Safety and Efficacy Trial of Diquafasol Tetrasodium (INS365) Ophthalmic Solution for the Treatment of Dry Eye

Tauber J, Kellerman D

Cornea 23 (8) 784-792, 2004.

Parasitic Keratitis and Conjunctivitis.

Tauber J, Jehan F.

In: Foster CS, Azar DT, Dohlman CH, Eds. *The Cornea, 4th Edition*, Philadelphia, Lippincott Williams & Wilkins, 2004, pp. 427-446.

Juvenile Rheumatoid Arthritis.

Tauber J

In: Krachmer JH, Mannis MJ, Holland EJ, Eds. Cornea, 2nd ed., St. Louis, CV Mosby, 2004.

Phase III Safety Evaluation of Cyclosporine 0.1% Ophthalmic Emulsion Administered Twice Daily to Dry Eye Disease Patients for Up to 3 Years.

Barber LD, Pflugfelder SC, Tauber J, Foulks GN

Ophthalmology 112: 1790-1794, 2005.

Wegener's Granulomatosis.

Choopong P, Tauber J, Foster CS.

Contemporary Ophthalmology in press, 2006.

Efficacy, Tolerability And Comfort Of A 0.3% Hypromellose Gel Ophthalmic Lubricant In The Treatment Of Patients With Moderate To Severe Dry Eye Syndrome.

Tauber J.

Current Medical Research and Opinions 23: 2629-2636, 2007.

Followup of Penetrating Keratoplasty.

Tauber J

In: Price, Ed. Curbside Consultation in Cornea and External Disease. Thoroughfare NJ, Slack, 2010 Amebiasis.

Tauber J.

in *Intraocular Inflammation*, ed. Zierhut, M, Ohno S, Orefice F, Pavesio C, Rao N. (Eds.) Springer Verlag, Heidelberg, Germany, 2011.

Giardiasis.

Tauber J.

in *Intraocular Inflammation*, ed. Zierhut, M, Ohno S, Orefice F, Pavesio C, Rao N. (Eds.) Springer Verlag, Heidelberg, Germany, 2011.

Juvenile Idiopathic Arthritis.

Tauber J

In: Krachmer JH, Mannis MJ, Holland EJ, Eds. Cornea, 3rd ed., St. Louis, CV Mosby, 2011.

Tear Osmolarity in the Diagnosis and Management of Dry Eye Disease

Lemp MA, Bron AJ, Baudoin C, Del Casillo B, Geffen D, Tauber J, Foulks GN, Pepose JS, Sullivan BD. *Amer. J Ophthalmology*, 2011; 151:792-798.

The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommitte on Management and Treatment of Meibomian Gland Dysfunction

Geerling G, Tauber J, Baudoin C, Goto E, Matsumoto Y, O'Brien T, Rolando M, Tsubota K, Nichols KK. *Investigative Ophthalmology & Visual Science*, Special Edition 2011, Vol. 52, No. 4; 2050-2064.

Scleritis Therapy

Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. *Ophthalmology*, 119: 51-58, 2012.

Clinical Characteristics of a large Cohort of Patients With Scleritis and Episcleritis

Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. *Ophthalmology*, 119: 43-50, 2012.

Clinical features and presentation of infectious scleritis from herpes viruses: a report of 35 cases.

Gonzalez-Gonzalez LA1, Molina-Prat N, Doctor P, Tauber J, Sainz de la Maza MT, Foster CS *Ophthalmology*. 119(7):1460-4, 2012

Is There a Difference Between the Various Corticosteroid Preparations?

Tauber J

In: Foster CS ed., Curbside Consultation in Uveitis: 49 Clinical Questions, Thoroughfare NJ, Slack, 2012: 41-44.

Parasitic Keratitis and Conjunctivitis.

Tauber J, Anzaar F.

In: Jaypee Brothers.

The Sclera, 2nd edition.

Ed. by Sainz de la Maza M, Tauber J, Foster CS. New York, Springer-Verlag, 2012. pp. 1-307.

Scleritis Associated with Inflammatory Bowel Disease

Sainz de la Maza M, Molina N, Alonso Gonzalez-Gonzalez L, Doctor PP, Tauber J, Foster CS, *Investigative Ophthalmology Visual Science, in press.*

The TFOS International Workshop on Contact Lens Discomfort: report of the management and therapy subcommittee.

Papas EB1, Ciolino JB, Jacobs D, Miller WL, Pult H, Sahin A, Srinivasan S, Tauber J, Wolffsohn JS, Nelson JD; members of the TFOS International Workshop on Contact Lens Discomfort *Invest Ophthalmol Vis Sci. 2013 Oct 18;54(11):TFOS183-203*.

Clinical features and presentation of posterior scleritis: a report of 31 cases

Gonzalez-Gonzalez LA, Molina-Prat N, Priyanka Doctor P, Tauber J, Sainz de la Maza M, Foster CS, *Ocular Immunology and Inflammation 2014 Jun;22(3):203-7*.

Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.

Tauber J, Karpecki P, Latkany R, Luchs J, Martel J, Sall K, Raychaudhuri A, Smith V, Semba CP; OPUS-2 Investigators. *Ophthalmology* 2015; 122:2423-2431.

Scleritis Associated with Relapsing Polychondritis

Sainz de la Maza M, Molina N, Alonso Gonzalez-Gonzalez L, Doctor PP, Tauber J, Foster CS, *British J Ophthalmology, 2016; in press.*

Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.

Goldstein MH1, Martel JR, Sall K, Goldberg DF, Abrams M, Rubin J, Sheppard J, Tauber J, Korenfeld M, Agahigian J, Durham TA, Furfine E

Eye Contact Lens. 2016 Jul 27.]

Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized Double-Masked, Placebo-Controlled Trial (OPUS-3).

Holland EJ, Luchs J. Karpecki PM, Nichols KK, Jackson MA, Sall K, Tauber J, Roy M, Raychaudhuri A, Shojaei A.

Ophthalmology 2017; 124:53-60.

TFOS DEWS II Management and Therapy Report

Jones L, Downie LE, Korb DR, Benitez-del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Craig JP:.

Ocular Surface (15); 573-628, 2017.

Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: combined evidence from 5 randomized Trials. Shojaei A, Darvish-Zargar M, Holland EJ, Chan CC, Nichols KK, Tauber J, Baudoin C, Raychaudhuri A, Roy M.

IOVS

A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.

Tauber J, Schechter B, Bacharach J, et. al.

Clinical Ophthalmology 2018:12 1921–1929

Pooled analysis of efficacy and safety of OTX-101, a novel nanomicellar cyclosporine formulation, in patients with keratoconjunctivitis sicca.

Toyos MM, Goldberg D, Tauber J, Malholtra R, Darby C, Ogundele O and Luchs J.

IOVS 2019, in press

Comparison of the iLUX and the LipiFlow for the treatment of meibomian gland function and symptoms: a randomized clinical trial.

Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore M.

Submitted to Am J Ophthalmol, 2019.

A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction.

Tauber J.

Cornea 2020: in press.

Efficacy of a propylene glycol/hydroxypropyl guar-based lubricant eye drop in improving tear stability in patients with dry eye disease.

Srinivasin S, Tauber J, et. al.

IOVS 2020, in press

1990-1992	Cyclosporine-High Risk Corneal Transplantation Study
1990-1996	VISX Photorefractive Keratectomy Study
1990-1995	Fibronectin Eyedrops in the Treatment of Nonhealing Corneal Ulcers
1992-1993	Efficacy of Carbomer Gel Versus Hypotears in Dry Eye Patients
1992-1994	Efficacy and Safety of Rimexolone Ophthalmic Suspension
	Versus Pred Forte 1% for the Treatment of Uveitis
1992-1993	Efficacy and Safety Evaluation of Lodoxamide 0.1% Ophthalmic
	Solution Versus Placebo in Vernal Keratoconjunctivitis
1992-1994	Adjunctive Therapy with Galardin TM Matrix Metalloproteinase
	Inhibitor in Patients with Corneal Ulcers Caused by Infection
1992-1994	Adjunctive Therapy with Galardin TM Matrix Metalloproteinase
	Inhibitor in Patients with Corneal Ulcers Caused by Rheumatoid Arthritis
1992-1993	A Clinical Study Evaluating the Ocular Safety, Comfort and Efficacy
	Of Cellufresh® Compared with Celluvisc®, Hypotears P.F.® and
	Tears Naturale II® in Subjects with Dry Eye Syndrome
1992-1993	A Prospective, Randomized, Double-Masked, Parallel Group, Two
	Week, Multicenter Comparison Trial of the Ocular Efficacy and Safety
	Of Voltaren Ophthalmic 0.1% Solution with That of Acular 0.5%
	Ophthalmic Solution in Patients with Acute Seasonal Allergic
	Conjunctivitis
1993-1994	Safety and Efficacy of Lotoprednol Etabonate in Acute Anterior Uveitis
1994-1995	A Clinical Study Comparing the Ocular Safety and Efficacy Of
	Acular With Livostin And Vehicle in Subjects with Seasonal Allergic
	Conjunctivitis
1994-1996	A Double-Masked, Double-Dummy, Randomized, Acyclovir
	Controlled, Parallel Group Study to Compare the Efficacy and
	Safety of Famciclovir With Acyclovir in The Treatment Of
100= 1007	Patients with Ophthalmic Zoster
1995-1996	A Dose-Ranging Study Evaluating the Safety, Tolerability, and
	Efficacy of Cyclosporine and Vehicle Ophthalmic Emulsions in
1996-1996	The Treatment of Moderate to Severe Keratoconjunctivitis Sicca
1990-1990	Comparison of Lotprednol Etabonate in Acute Anterior Uveitis and Placebo in the Treatment of Inflammation Following Cataract
	Surgery with Intraocular Lens Implantation
1996-1997	Multicenter Comparison of the Comfort and Efficacy of Genteal
1770-1777	Ophthalmic Lubricant Solution Versus Refresh Plus Ophthalmic
	Lubricant Solution in the Treatment of Patients with Dry Eye Syndrome
1997-1998	A randomized double-masked (investigator), active-controlled, parallel
1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Evaluation of the safety and efficacy of Cidofovir topical ophthalmic solution in the
	treatment of viral epidemic keratoconjunctivitis
1997-1998	A Randomized, Single-Masked (Investigator), Active-Controlled, Parallel
	Evaluation of The Safety and Efficacy of Cidofovir Topical Ophthalmic
	Solution in The Treatment of Herpes Epithelial Keratitis
1997-1998	A Safety and Efficacy Assessment of Hyaluronidase Solution Injected Into
	The Vitreous Body of The Eye to Hasten the Clearing of Blood from the
	Vitreous

1997-1998 1998-1999	A Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study of the Safety and Efficacy of Cyclosporine 0.05% And 0.1% Ophthalmic Emulsions Used Twice Daily for Up to One Year In Patients with Moderate to Severe Keratoconjunctivitis Sicca A Six Month, Multicenter, Triple-masked, Placebo-Controlled Adjunctive Therapy Study of the Safety and Efficacy of AL-6221 0.0015% and AL-6221 0.004% Ophthalmic Solution in Patients With
1998-2000	Open Angle Glaucoma or Ocular Hypertension Maintained on Timoptic 0.5% A Phase III Study of MDX-RA Compared with Placebo Administered in Patients Undergoing Extracapsular Extraction with Phacoemulsification For Cataract
1998-1999	A Multicenter, Open-Label, Phase 2 Study Extension Evaluating the Safety of Cyclosporine 0.1% Ophthalmic Emulsion Used Twice Daily for Up to One Additional Year in Patients with Moderate to Severe
1998-2000	Keratoconjunctivitis Sicca A Multicenter, Open-Label, Phase 3 Study Extension Evaluating the Safety of Cyclosporine 0.1% Ophthalmic Emulsion Used Twice Daily for One Additional Year in Patients with Moderate to Severe Keratoconjunctivitis Sicca Previously Dosed for 6 to 12 Months with
1998-2001	Cyclosporine 0.05% or 0.1% Safety and Efficacy Study of Vitrase (Hyaluronidase) for Ophthalmic Intravitreal Injection for Clearance of Severe Vitreous Hemorrhage Study
1998-1999	RUF366 A Pilot Study of Zenarestat 0.3% (RUF366) For the Treatment of Corneal Epitheliopathy Associated with Diabetes Mellitus
1998-1999	Genteal-Gel Ophthalmic Lubricant in the Treatment of Patients with Moderate to Severe Dry Eye Syndrome
1999-2005	A 48 Month, Multicenter, Randomized, Double-Masked, Placebo- Controlled, Clinical Study to Evaluate the Effectiveness and Safety Of Oral Memantine In Daily Doses Of 20mg and 10mg In Patients With
2000-2001	Chronic Open Angle Glaucoma at Risk for Glaucomatous Progression Cyclosporine 0.05% Ophthalmic Emulsion vs Tears Naturale Free Used Twice Daily in Increasing Daily Lens Comfort and Wear Time
2000-2001	Joseph Tauber, M.D., Primary Investigator Memantine Oral Doses of 20mg and 10mg In Patients with Chronic Open-Angle Glaucoma at Risk for Glaucomatous Progression
2001-2002	Inspire 365 Ophthalmic Solution vs Placebo in Patients with Moderate to Severe Dry Eye Disease
2001-2002	A Multicenter Evaluation of Strategies to Optimize the Tolerability of Restasis 0.05% Ophthalmic Emulsion
2001-2004	Randomized, 5 Year Postmarketing Safety Study of Xalatan Compared to "Usual Care" in Patients with Open-Angle Glaucoma or Ocular
2001-2004	Hypertension A Three Month Clinical Study Comparing the Efficacy and Tolerability of Alphagan and Xalatan in subjects with Chronic Open-Angle Glaucoma or Chronic Ocular Hypertension Presently on Topical Beta Blockers

2001-2004	A Four-Month, Randomized, Double-Masked, Parallel Group, Two-Arm
	Study Comparing the Safety and Efficacy of Alphagan™ 0.2%/Xalatan™ 0.005%
	Combination Therapy and Cosopt™ Combination Therapy for the Reduction
	Of Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension
2001-2003	A Multi-Center, Parallel, Randomized, Double-Masked, Vehicle-Controlled, Dose Ranging
	Study to Evaluate the Safety, Tolerability and Efficacy of Testosterone 0.01%, 0.1%, and
	0.3% Ophthalmic Solutions Administered Twice Daily for 16 weeks in Patients with
2001 2002	Keratoconjunctivitis Sicca
2001-2003	A Multi-Center, Double- Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects with Dry
	Eye Disease.
2001-2002	A Prospective, Randomized, Parallel-group, Multi-center, Double-masked Trial Comparing
2001 2002	the Efficacy and Safety of 1.5% Levofloxacin Ophthalmic Solution with 0.3% Ofloxacin
	Ophthalmic Solution for Treating Bacterial Keratitis.
2004-2005	A 21 Day, Pilot, Multicenter, Investigator-masked Randomized Parallel Comparison
	of the Safety and Efficacy of Gatifloxacin 0.3% Ophthalmic Solution Compared with
	Ciprofloxacin 0.3% Ofloxacin Ophthalmic Solution in Patients with Acute Bacterial Corneal
	Ulcers.
2004-2005	A Multi-Center, Parallel Group, Double- Masked, Randomized, Placebo-Controlled Study of
	Multiple Ocular Instillations of Diquafasol Tetrasodium Ophthalmic Solution, 2% in Subjects
2004 2005	with Dry Eye Disease.
2004-2005	Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multi-Center, Phase 3,
2005 2007	Randomized, Double-Masked, Placebo-Controlled, Parallel Group, 26 Week Study.
2005-2007	A 24 week randomized, double-blind, multicenter, parallel-group, placebo-controlled evaluation of the safety and efficacy of 0.3% and 1% pimecrolimus ophthalmic suspensions
	used twice daily in patients with moderate to sever keratoconjunctivitis sicca.,
2005-2006	Optimization of Clinical Testing in Patients with Dry Eye.
2005-2007	A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 compared to
2002 2007	Vigamox TM in the Treatment of Bacterial Conjunctivitis.
2005-2007	Randomized, Double-Masked Study of Rimexolone 0.2% and Vehicle in Treatment of Dry
	Eye.
2006-2009	A Double-Masked, Placebo-Controlled, Parallel Group, Multi-center, Dose-ranging Study to
	Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight
	Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior- or Pan-
•00 < •000	Uveitis
2006-2009	A Double-Masked, Placebo-Controlled, Parallel Group, Multi-center, Dose-ranging Study to
	Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Clinically Quiescent
	Sight Threatening, Non-Infectious Intermediate-, Anterior and Intermediate-, Posterior- or Pan- Uveitis
2006-2009	A Double-Masked, Placebo-Controlled, Parallel Group, Multi-center, Dose-ranging Study to
2000 2009	Assess the Efficacy and Safety of LX211 as Therapy in Subjects with Active Sight
	Threatening, Non-Infectious Anterior Uveitis
2007-2009	A Multi-center, Placebo-Controlled, Randomized, Parallel-Group Dose-Ranging
	Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft
	Rejection Episodes and Graft Failure Following Penetrating Keratoplasty with LX201
	Implantation In Subjects Who Are At Increased Immunological Risk
2007-2009	A Multi-center, Placebo-Controlled, Randomized, Parallel-Group Dose-Ranging
	Study to Assess the Efficacy and Safety of LX201 Implantation for the Prevention of
	Corneal Allograft Rejection Episodes or Graft Failure in Subjects Who Have
	Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
	Experienced one of more respection Episodes I onowing I encutuing relative

2007-2008	A Phase III Study of the Efficacy and Safety of Cyclosporine Ophthalmic Solution, 0/1%
	(STA-603) Compared to Vehicle in Subjects with Moderate to Severe Dry Eye Syndrome
2007-2008	A Phase 2b Multicenter, Randomized, Double-Masked Study of the Safety and Efficacy of
	Difluprednate 0.05% Ophthalmic Emulsion Compared to Prednisolone Acetate 1%
	Ophthalmic Suspension in the Treatment of Endogenous Anterior Uveitis
2007-2008	CR-1485CJ Evaluation of Multifocal Soft Contact Lens Designs
2008-2009	A Multi-Center, Open-Label, Randomized, Pilot Study of the Safety and Efficacy of Azasite
	Ophthalmic Solution 1% in Combination with Mechanical Therapy vs. Mechanical Therapy
	Alone in Subjects with Blepharitis
2008-2009	Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients with Facial
	Rosacea
2008-2009	A Phase II Randomized, Masked, Parallel-Group Study of Safety and Preliminary
	Efficacy of the Latanoprost Punctum Plug Delivery System in Subjects with Primary Open
	Angle Glaucoma or Ocular Hypertension
2008-2009	An Open-Label Proof-Of-Concept Study to Assess The Effects of Two AIN457 Doses (on
	Day 1 and Day 22) In Patients With Noninfectious Uveitis
2009-2009	A Multicenter, Parallel Group, Double-masked, Randomized, Placebo-controlled Study of The
	Effects of Diquafasol tetrasodium Ophthalmic Solution, 2% In Subjects with Dry Eye Disease
	and a Central Corneal Staining Score of 3 (NEI Scale)
2009-2009	An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5%
	for the Treatment of Bacterial Conjunctivitis in the USA
2009-2012	A Device Evaluation Study to Assess the Physical and Clinical Performance of Prototype
	Punctal Plug Design Iterations
2009-2009	An Open-Label, Phase 2 Study of Punctal Placement of the Latanoprost Punctal Plug
	Delivery System (L-PPDS in Subjects with Ocular Hypertension (OH) or Open-Angle
	Glaucoma (OAG)
2009-2009	A Phase I/II Prospective, Randomized, Double Masked, Vehicle and Comparator Controlled,
	Dose Ranging Study of CP-690,550 In Subjects with Dry Eye Disease
2009-2009	A Multi-Center, Open Label Randomized Pilot Study of the Safety and Efficacy of Azasite
	Ophthalmic Solution, 1% in Combination with Mechanical Therapy versus Mechanical
	Therapy Alone in Subjects with Blepharitis
2009-2010	A Clinical Safety and Efficacy Evaluation of Zylet® (loteprednol etabonate 0.5%
	and tobramycin 0.3% ophthalmic suspension) compared to Lotemax® (loteprednol
	etabonate ophthalmic suspension 0.5%), Tobramycin Ophthalmic Solution USP, 0.3%,
	and the Vehicle of Zylet® for the Treatment of Blepharoconjunctivitis in Pediatric
	Subjects
2009-2010	A Multi-Center, Double Masked, Placebo-Controlled, Parallel-Group, Randomized Study
2007 2010	of the Safety and Efficacy of Azithromycin Ophthalmic Solution, 1% versus Placebo for
	Four Weeks in Subjects with Dry Eye Disease
2010-2011	A Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Multicenter,
2010-2011	Exploratory Study Assessing Safety and Efficacy of BOL-303242-X Ophthalmic
2011 2011	Suspension in Dry Eye Syndrome A Bandomized Multi Center Double Marked Vakiele Centralled Parallel Crown
2011-2011	A Randomized, Multi-Center, Double-Masked, Vehicle- Controlled, Parallel-Group,
	Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% versus Vehicle for
2011 2012	Four Weeks in Subjects with Blepharitis
2011-2013	A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3
	Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic
	Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate (1%)
	in Patients with Non-Infectious Anterior Segment Uveitis

2012-2013	A Randomized, Double-Masked, Parallel –Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 (1.0% Azithromycin and 0.1% Dexamethasone) Compared to Azasite alone, Dexamethasone 0.1% alone and Vehicle in the Treatment of Patients with Non-Bacterial Blepharitis
2012-2013	A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of 2% Rabamipide versus placebo in the treatment of Dry Eyes.
2012-2013	A Randomized, Double-masked, Placebo-controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution versus Placebo in subjects with Dry Eye Syndrome.
2013-2013	A Phase 3, Multicenter, Randomized, Double Masked and Placebo Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution
2013-2013	Compared to Placebo in Subjects with Dry Eye Currently Using Artificial Tears (OPUS-2) A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of GevokizumAb in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan-Uveitis
2013-2013	A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of GevokizumAb in the Treatment of Subjects with Non-infectious Intermediate, Posterior, or Pan- uveitis Currently Controlled with Systemic Treatment
2013-2014	Ophthalmic AGN195263 for the Treatment of Meibomian Gland Dysfunction
2014- 2015	A Multi-Center, Double-Masked, Randomized, Placebo Controlled Study of EBI-005
	Ophthalmic Solution versus Placebo in Subjects with Dry Eye Disease
2014-2015	A Double-Masked, Randomized, Multicenter, Placebo Controlled, Parallel-Group Study of
	SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of
	SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With
	Moderate to Severe Corneal Epithelial Disorders
2014-2015	A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in
0044 0045	Postsurgical Inflammation
2014-2015	A Phase 2, Double-Masked, Randomized, Vehicle Controlled Study to Evaluate
	the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of
2014 2017	Inflammatory Meibomian Gland Disease
2014-2016	Dry Eye Assessment and Management (DREAM) Study (NIH Sponsored Trial)
2014-2015	A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study
	Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic
2014 2015	Solution Compared to Placebo in Subjects with Dry Eye Disease
2014-2015	A Multicenter, Double-Masked, Parallel-Group, Vehicle Controlled Study to Assess
	the Efficacy and Safety of Rx-10045 Nanomicellar Ophthalmic Solution for
2014 2015	Treatment of Ocular Inflammation and Pain In Subjects Undergoing Cataract Surgery
2014-2015	A Randomized, Multicenter, Double-Masked, Vehicle Controlled, Dose-Ranging
	Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis
2014 2015	Sicca The state of
2014-2015	Evaluation of a Lubricant Eye Drop on Tear Lipid Layer Thickness in Contact Lens
004 F 004 C	Wearers
2015-2016	A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate
2015 2017	the Safety and Efficacy of NS2 Eye Drops in Patients with Anterior Uveitis
2015-2016	A Phase 3, Multicenter, Randomized, Double-masked, and Placebo Controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects with Dry Eye Disease and History of Recent Artificial Tear Use

2016-2017	Randomized, Double-Masked, Parallel Group Study of P - 321 Ophthalmic Solution
	Compared to Placebo in Subjects with Dry Eye Disease Assessing Safety and Efficacy Over 28 Days
2016-2017	A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group
	Study of SJP-0035 Ophthalmic Solution Compared with Placebo to Assess Safety
	and Efficacy of Two Dose Concentrations of SJP-0035 Ophthalmic Solution for
	Corneal Epithelial Wound Healing in Patients with Moderate to Severe Corneal
	Epithelial Disorders
2016 – 2017	An Open-Label Extension of a Randomized, Multicenter, Double-Masked, Vehicle-
_010 _011	Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of
	Keratoconjunctivitis Sicca
2016 - 2018	A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25%
	Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease
2016-2018	Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic
	Dexamethasone Phosphate Ophthalmic Solution in Patients With Non-Infectious
	Anterior Segment Uveitis
2016-2017	A Phase 3, Multi-Center, Double-Masked, Randomized, Parallel-Group Study to
	Assess Loteprednol Etabonate (BID and TID) versus Vehicle Gel for the Treatment of
	Ocular inflammation
2016 - 2017	An Open-Label Extension of a Randomized, Multicenter, Double-Masked, Vehicle-
	Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of
2017 2010	Keratoconjunctivitis Sicca
2017 – 2019	A Phase 3 Randomized, Double-Masked, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects with Non-
	Infectious Anterior Uveitis
2017-2017	Randomized Comparison between iLux TM and LipiFlow® in the Treatment of
	Meibomian Gland Dysfunction
2017 - 2018	Development of a Photographic Ocular Surface Grading Scale for Corneal and
	Conjunctival Staining in Subjects with Dry Eye Complaints
2017 – 2018	Clinical Evaluation Following Use of Systane Balance in Subjects with Lipid-
2017 – 2018	Deficient Dry Eye A Single-Center, Evaluation of a Single Vectored Thermal Pulsation Treatment vs.
2017 - 2016	
	Lifitegrast 5% Used Twice Daily in Patients with Inflammatory Meibomian Gland Disease
2018 – Present	
2018 – Present	A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients with Atopic
	Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic
	Conjunctivitis
2018 – Present	A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-
	Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen
	Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis
4010 D	Implantation
2018 – Present	A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy
	and Safety of Lacripep TM in Subjects with Dry Eye Associated with Sjögren's Syndrome

2018 – 2019	An Investigator-Masked, Randomized, Parallel-Group Study of the Ocular
	Tolerability of Voclosporin Ophthalmic Solution versus Restasis® in Subjects with Dry Eye Disease
2018 – 2019	A double-masked, randomized, multicentre, placebo-controlled, parallel-group study to access the safety and efficacy of SJP-0035 0.001% for the treatment of patients with
2018 – 2019	Dry Eye Disease with moderate to severe corneal epithelial disorders A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing
2018 – 2019	Regimens on Signs and Symptoms of Dry Eye Disease Evaluation of the Clinical Efficacy and Tolerability of SYSTANE Complete in Adult Patients with Dry Eye Disease following Topical Ocular use for 4 Weeks: A
2018 – 2020	Multicenter Trial A Phase III, Randomized, Double-Masked, Active-Controlled, Parallel-Group, Multi-center Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% Compared with Timolol Maleate Ophthalmic Solution 0.5% in Subjects with
2019 – 2020	Glaucoma or Ocular Hypertension - Spectrum 3 Study A Multi Center, Double-Masked, Randomized Placebo Controlled Study to Evaluate the Efficacy and Safety of HY02 in Subjects with Inflamed Meibomian Gland Dysfunction
2019 – 2019	A Single-Center Evaluation of HD Analyzer Measures in the Evaluation of Patients
	with Dry Eye Disease.
2019 - 2020	A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled,
	Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in
	Participants with Presbyopia
2019 - 2019	Comparison between iLux and LipiFlow in the treatment of Meibomian Gland
	Dysfunction (MGD): A 12 month, Multicenter study
2019 – Present	A 4 weeks, Phase II, multicenter, randomized, double-masked, vehicle-controlled, parallel group study with 12 weeks of follow-up to evaluate safety and efficacy of recombinant human Nerve Growth Factor (rhNGF) eye drops solution versus vehicle in patients with moderate to severe dry eye (DE)
2019 – Present	An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients with Atopic Keratoconjunctivitis, Vernal
2019 – Present	Keratoconjunctivitis, and Perennial Allergic Conjunctivitis Novaliq, NVU-003 Study: A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease associated with Meibomian Gland
2019 – Present	Dysfunction A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects with Dry Eye Disease (STRIDE 3)
2019 – Present	Thermal compression for optimization of keratometry in patients with Meibomian Gland Dysfunction before biometry